<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439283</url>
  </required_header>
  <id_info>
    <org_study_id>A R C R 2003 - 01 / PO 3353</org_study_id>
    <nct_id>NCT00439283</nct_id>
  </id_info>
  <brief_title>Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis</brief_title>
  <official_title>Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis: Comparison of Infusion Every 6 Weeks Versus Infusion on Demand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association de Recherche Clinique en Rhumatologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association de Recherche Clinique en Rhumatologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous treatment with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
      is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in
      disease relapse, with variable delay. Objective of this study was to compare efficacy between
      a continuous treatment with infliximab, and a treatment adapted to symptoms recurrence.
      Addition of methotrexate (MTX)to infliximab was also tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with active AS were randomly assigned to receive infliximab every 6 weeks (Q6), or
      only upon symptoms recurrence (on-demand), following a loading regimen of infusions at weeks
      0, 2, and 6. Patients in the latter group were randomly assigned to receive MTX or not,
      starting 4 weeks prior to infliximab. Monitoring was performed over one year. The primary end
      point was the proportion of patients with a 20% improvement response according to the
      ASsessment in Ankylosing Spondylitis (ASAS) criteria, at week 54.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point was the proportion of patients with a 20% improvement response according to the ASAS criteria, at week 54.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of the ASAS50 and ASAS70.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who experienced a partial remission, according to ASAS definition.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in independent components of the ASAS response criteria.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASDAI.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schober test.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finger to floor test.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest expansion score.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occiput-to-wall measurements.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute-phase reactants (erythrocyte sedimentation rate and C-reactive protein level).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions administered after the loading regimen.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring an increase in the dose of infliximab.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curves (AUCs) of the BASDAI recorded on a weekly basis on automatic phone server, calculated from week 0 through week 54.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curves (AUCs) of the global pain scores recorded on a weekly basis on automatic phone server, calculated from week 0 through week 54.</measure>
  </secondary_outcome>
  <enrollment>240</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt; 18 years old)

          -  With a diagnosis of AS

          -  With at least one of the following evidences for active inflammation, present within 3
             months before inclusion: a serum C-reactive protein (CRP) level above twice the upper
             limit value of the normal range, a positive magnetic resonance imaging of the spine or
             sacro-iliac joints, a vascularized enthesitis by power-Doppler ultrasound technic.

          -  Presence of clinically active axial disease, as defined by 1) a Bath AS Disease
             Activity Index (BASDAI) (18) of ≥ 3/10, and 2) a score of ≥ 3/10 for axial pain
             (second item of BASDAI).

          -  Disease-modifying antirheumatic drugs (DMARDs), such as sulphasalazine, methotrexate,
             hydroxychloroquine, intra-muscular gold, thiol compound, cyclosporin, intravenous
             biphosphonate had to be discontinued for at least 4 weeks before inclusion.

          -  Dosages of NSAIDs and corticosteroid were required to remain stable for at least 4
             weeks before inclusion.

          -  A negative pregnancy test result was required for non menopausal female patients, and
             contraception during the study period and for six months after the last infusion of
             infliximab was recommended to all patients of childbearing potential.

        Exclusion Criteria:

          -  Pregnancy.

          -  Breastfeeding.

          -  Vaccination with a live organism during the last month.

          -  Present infection or any episode of serious infection within the last three months.

          -  Active malignancy within the previous five years.

          -  Alcohol or drug addiction.

          -  Severe chronic concomitant disease.

          -  Administration of an investigational drug within the last three months, or of any
             known TNF inhibitor therapy in the past (such as thalidomide, infliximab or
             etanercept).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime DOUGADOS, Professor</last_name>
    <role>Study Director</role>
    <affiliation>ARCR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gilles de Corbeil</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Général</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Havre</name>
      <address>
        <city>Le Havre</city>
        <zip>76083</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Philibert</name>
      <address>
        <city>Lomme</city>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH St Joseph - St Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69365</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Porte Madeleine</name>
      <address>
        <city>Orléans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy-Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <last_update_submitted>February 26, 2007</last_update_submitted>
  <last_update_submitted_qc>February 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2007</last_update_posted>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>infliximab</keyword>
  <keyword>Systematic regimen</keyword>
  <keyword>On-demand regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

